{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    8,
    24,
    40,
    41,
    52,
    53,
    55,
    57
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Accelerated Elimination Procedure",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.1.1",
        "sectionTitle": "Noninvestigational medicinal product",
        "description": "Reference for procedures following intervention period for male and female participants"
      },
      {
        "id": "ref_2",
        "name": "Contraception Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference for highly effective contraceptive methods"
      },
      {
        "id": "ref_3",
        "name": "Country-specific Contraception",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.11",
        "sectionTitle": "Appendix 9: Country-Specific Requirements",
        "description": "Reference for specific requirements in UK, Germany, and Denmark"
      },
      {
        "id": "ref_4",
        "name": "Informed Consent Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1.3",
        "sectionTitle": "Appendix 1: Regulatory, Ethical, and Study Oversight Considerations",
        "description": "Reference for legally authorized representative signature requirements"
      },
      {
        "id": "ref_5",
        "name": "TB Screening",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Appendix 2: Clinical Laboratory Tests",
        "description": "Description of screening tests for Tuberculosis"
      },
      {
        "id": "ref_6",
        "name": "Liver Safety Algorithm",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.6",
        "sectionTitle": "Appendix 6: Liver and other safety: actions and follow-up assessments",
        "description": "Reference for IMP discontinuation criteria and safety algorithms"
      },
      {
        "id": "ref_7",
        "name": "Drug Metabolism Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.8",
        "sectionTitle": "Appendix 8A: Examples of Drugs with a Potential to Change SAR442168 Metabolism",
        "description": "List of prohibited CYP3A inducers and CYP2C8 inhibitors"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Sanofi corporation organized and existing under the laws of France is the ultimate parent of a worldwide group of affiliates",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Sponsor Name",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "All assessments shall be done as designated in this SoA unless not permitted according to local regulations.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "1.3 Schedule of Activities (SoA)",
        "pageNumber": 25
      },
      {
        "id": "annot_3",
        "text": "The interval between screening and randomization visits can range from 11 days (minimum) to 28 days (maximum).",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Footnote a",
        "pageNumber": 25
      },
      {
        "id": "annot_4",
        "text": "The Investigator may consult with an infectious disease expert if required, eg, test results are unclear or there is a suspicion of false positive test results.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.2 Exclusion Criteria - E 02",
        "pageNumber": 42
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1 (electronic 15.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-12-20",
        "description": "Include liver function test monitoring guidance and update co-medication guidance per Health Authority request",
        "amendmentNumber": "11"
      },
      {
        "id": "ver_2",
        "versionNumber": "1 (electronic 14.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-11-17",
        "description": "Amended Clinical Trial Protocol 10",
        "amendmentNumber": "10"
      },
      {
        "id": "ver_3",
        "versionNumber": "1 (electronic 1.0)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-02-28",
        "description": "Original Protocol",
        "amendmentNumber": "Original"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}